Golar LNG Limited – Q4 2023 results presentation
Golar LNG’s 4th Quarter 2023 results will be released before the NASDAQ opens on Thursday, February 29, 2024. In connection […]
Puyi Inc. Announces Amendment to the Proposed Chinese Name to Be Resolved at the Extraordinary General Meeting on February 22, 2024
GUANGZHOU, China, Feb. 05, 2024 (GLOBE NEWSWIRE) — Puyi Inc. (NASDAQ: PUYI) (“Puyi” or the “Company”), a leading third-party wealth […]
Tritium Customers Win Largest Share of Round 1 Tennessee NEVI Program
LEBANON, Tenn., Feb. 05, 2024 (GLOBE NEWSWIRE) — Tritium DCFC Limited (Tritium) (Nasdaq: DCFC), a global leader in direct current […]
Haynes International Announces Agreement to be Acquired by North American Stainless, a Wholly Owned Subsidiary of Acerinox
Haynes Stockholders to Receive $61.00 Per Share in Cash, Delivering Significant and Immediate Value In Connection with Transaction, Acerinox will […]
VEON and Kyivstar Welcome Former U.S. Secretary of State and Kyivstar Board member Mike Pompeo to Ukraine
Kyiv, 5 February 2024 – VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and […]
NOVONIX Appoints Sharan Burrow AC to Board of Directors
BRISBANE, Australia, Feb. 05, 2024 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or “the Company”), a leading […]
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; […]
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
Subgroup analyses underscore favorable clinical profile and durability of EYP-1901 Presentations highlight previously reported positive Phase 2 DAVIO 2 topline […]
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity […]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 02, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical […]
